Reino Unido autoriza Redemplo de Arrowhead para adultos con síndrome de quilomicronemia familiar
- REDEMPLO (plozasiran), de Arrowhead Pharmaceuticals, obtuvo autorización en Reino Unido para reducir los triglicéridos en adultos con síndrome de quilomicronemia familiar.
- NICE recomienda financiarlo en Inglaterra y Gales para adultos con diagnóstico genético confirmado y respuesta insuficiente a dieta y tratamientos convencionales.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261027614909) on October 27, 2026, and is solely responsible for the information contained therein.